National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 5) (No. PB 40 of 2012)

Link to law: https://www.comlaw.gov.au/Details/F2012L01332

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 40 of 2012
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 5)
 
National Health Act 1953
___________________________________________________________________________
 
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 20 June 2012
 
 
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
 
 
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 5).
 
(2)                This Instrument may also be cited as PB 40 of 2012.
 
2             Commencement
                This Instrument commences on 1 July 2012.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
 
[1]    Section 3, Definition for diluent fee
omit:                    $4.75
substitute:          $4.83
[2]    Section 3, Definition for dispensing fee
omit:                    $6.42
substitute:          $6.52
[3]    Section 3, Definition for distribution fee
omit:                    $24
substitute:          $24.38
[4]    Section 3 Definition for preparation fee
omit:                    $40
substitute:          $40.64
[5]    Schedule 1 Part 1, entry for Bortezomib
substitute:
Bortezomib
Powder for injection 3.5 mg
Injection
Velcade
JC
MP
C3762 C3763 C3764 C3765 C3766 C3767
D                                   
 
[6]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 160 mg in 16 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed ‘Circumstances’
insert after C3890:
C3892
 
[7]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed ‘Circumstances’
insert after C3890:
C3892
[8]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed ‘Circumstances’
insert after C3890:
C3892
[9]    Schedule 1 Part 1, after entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL with manner of administration Injection and brand Irinotecan Actavis 500
insert in the columns in the order indicated:
 
 
 
Irinotecan Alphapharm
AF
MP
C3184
D
 
[10]  Schedule 2, after entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate) with manner of administration Oral and brand Zofran
insert in the columns in the order indicated:
 
 
 
Zondan
GM
EMP
C3050
 
4
0
 
 
[11]  Schedule 2, after entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate) with manner of administration Oral and brand Zofran
insert in the columns in the order indicated:
 
 
 
Zondan
GM
EMP
C3050
 
4
0
 
 
[12]  Schedule 2, after entry for Ondansetron in the form Tablet (orally disintegrating) 4 mg with manner of administration Oral and brand Ondansetron ODT-DRLA
insert in the columns in the order indicated:
 
 
 
Onsetron ODT 4
WQ
EMP
C3050
 
4
0
 
 
[13]  Schedule 2, after entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg with manner of administration Oral and brand Ondansetron ODT-DRLA
insert in the columns in the order indicated:
 
 
 
Onsetron ODT 8
WQ
EMP
C3050
 
4
0
 
 
 
[14]  Schedule 3, after entry for GK
insert in the columns in the order indicated:
GM
Ascent Pharma Pty Ltd
 68 118 734 795
 
[15]  Schedule 3, entry for GZ
substitute:
GZ
sanofi-aventis Australia Pty Ltd
 31 008 558 807
 
 
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.frli.gov.au.